Aten

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aten

Quick Facts

Property Description
Active ingredient Atenolol
Pharmacological class Beta-Adrenergic Receptor Antagonist (Beta Blocker)
Origin Synthetic compound
Route of administration Oral (Tablet), Intravenous (Injection)
Characteristic Cardioselective (beta-1 selective)

What is Aten (Atenolol) and What Type of Medicine Is It?

Aten is a prescription-only medicine whose active ingredient is Atenolol (INN), a widely utilized synthetic compound. Atenolol is officially classified as a Beta-Adrenergic Receptor Antagonist, commonly known as a Beta Blocker. The drug is recognized due to its designation as a second-generation beta-1-selective adrenergic antagonist, a characteristic that differentiates its action from older, non-selective agents by preferentially targeting receptors primarily in the heart.

Composition, Origin, and Available Forms

The substance Atenolol (C14H22N2O3) is characterized chemically as a hydrophilic compound, a property supported by pharmacological studies that demonstrate limited passage across the blood-brain barrier. This helps focus its primary therapeutic action peripherally on the cardiovascular system. As a single-ingredient product, Atenolol is available in two systemic dosage forms: the Oral Tablet, intended for sustained, long-term management, and an injectable solution for Intravenous Injection, reserved for acute clinical settings requiring immediate control.

General Purpose and Primary Physiological Benefit

The overarching therapeutic goal of Atenolol is to reduce strain and promote stability within the cardiovascular system over time. This function is achieved by modulating the heart's response to stress hormones, thereby reliably decreasing the heart rate and the force of myocardial contraction. The use of Atenolol is therefore integrated into the long-term management plan for adult patients requiring sustained regulation of their cardiovascular metrics.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Aten?

Possible Side Effects and Safety Information

The safety profile of Aten (Atenolol) is documented by governmental regulatory agencies, categorizing adverse reactions by frequency and the body's organ systems affected. This information strictly reflects official prescribing labels and does not constitute medical advice or instructions for use.


Frequency-Classified Adverse Reactions

Frequency Category Documented Adverse Reactions (Examples)
Common (1% to 10%) Fatigue/Tiredness, Cold extremities, Bradycardia (slow heart rate), Gastrointestinal disturbances.
Uncommon (0.1% to 1%) Sleep disturbances, Mood alterations.
Rare (0.01% to 0.1%) Dry eyes, Visual disturbances, Paresthesia, Thrombocytopenia, Dermatological Reactions.
Very Rare (<0.01%) Agranulocytosis.

Adverse effects are also grouped by System-Organ Class (SOC), including Cardiac disorders, Vascular disorders, Nervous system disorders, and Gastrointestinal disorders.


Serious Adverse Reactions and Safety Limitations

Official labeling highlights serious adverse reactions, which include the potential for worsening of heart failure in susceptible patients and the precipitation of second- or third-degree atrioventricular (AV) block.

Safety-related restrictions stipulate that Aten is contraindicated in specific pre-existing conditions, such as overt cardiac failure, cardiogenic shock, severe bradycardia, and most cases of heart block.

Population-Specific Considerations

  • Pregnancy: Use during the third trimester is associated with risks including fetal growth restriction and neonatal bradycardia or hypoglycemia.
  • Renal Impairment: Dose adjustments are required for patients with impaired renal function, as the drug is primarily eliminated through the kidneys.

Note: Patients taking beta-blockers may be non-responsive to the standard dose of epinephrine used to treat anaphylactic reactions, a high-level safety consequence included in regulatory documents.

Overdose and Emergency Response

An overdose of Aten (atenolol) can be a medical emergency, as it is a beta-blocker that primarily affects the cardiovascular system. Overdose symptoms usually manifest within one to two hours of ingestion and can be severe, potentially leading to death if not treated promptly.

Symptoms of Aten Overdose

Overdose effects often result from exaggerated therapeutic actions, primarily on the heart. Key symptoms include:

  • Cardiovascular: Profoundly slow heart rate (bradycardia), low blood pressure (hypotension), irregular heartbeat, and signs of heart failure (e.g., shortness of breath, swelling of the legs).
  • Respiratory: Difficulty breathing, wheezing, especially in individuals with existing lung conditions like asthma.
  • Neurological: Drowsiness, confusion, weakness, excessive tiredness, and potentially seizures or coma in severe cases.
  • Metabolic: Low blood sugar (hypoglycemia), which can be particularly concerning in children, or in patients who are fasting or diabetic, and may mask the usual signs of low blood sugar like a rapid heartbeat.

When to Seek Help

If you suspect an Aten overdose, even if the person appears well, seek emergency medical assistance immediately. Do not wait for severe symptoms to develop. Contact a national poison control center or your local emergency services. Be prepared to provide the person's age, weight, condition, the name and strength of the medicine, the amount swallowed, and the time of ingestion.

Treatment often involves supportive care, monitoring of vital signs (heart rate, blood pressure, blood sugar, and EKG), and may include activated charcoal, intravenous fluids, and specific medications to counteract the drug's effects, such as atropine, glucagon, or high-dose insulin therapy.

Therapeutic Uses of Aten

What Aten Treats: Main Uses and Benefits

Atenolol is commonly used for managing high blood pressure (hypertension) and providing sustained support to the heart. This therapeutic strategy helps lower the risk of cardiovascular complications, which contributes to the long-term maintenance of cardiovascular stability.


The medication is relevant in conditions involving episodic or fluctuating manifestations, such as angina pectoris (chest pain) and certain cardiac dysrhythmias. It is applied in contexts where additional symptomatic support is needed when symptoms create noticeable physiological strain.

“Atenolol is used across domains where additional symptomatic support is needed, helping ease the overall symptom load during periods of heightened symptoms.”

In these contexts, it helps address symptom clusters like abnormal heart rates and pressure. This supports patients during episodes of heightened discomfort and **provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Cardiovascular Strain
Primary Focus Sustained reduction of pressure and strain on the heart muscle.
Symptom Scope High blood pressure, recurrent chest pain, and rapid heart rate.
Benefit Contributes to easing the overall symptom load during symptomatic periods.

Regulatory References

  1. U.S. National Library of Medicine DailyMed label for Atenolol

Eligibility and Restrictions for Use

Who Can and Cannot Use Aten (Atenolol)

Official regulatory documents define strict criteria for the use of Atenolol, focusing on population eligibility and absolute contraindications. Use is approved for adult patients managing hypertension, angina pectoris, and post-myocardial infarction.

Absolute Contraindications

Atenolol is contraindicated and must not be used in the presence of several serious, uncontrolled cardiac and metabolic conditions. This includes cardiogenic shock, uncontrolled heart failure, second- or third-degree atrioventricular (AV) heart block, severe symptomatic bradycardia, sick sinus syndrome, and metabolic acidosis. It is also prohibited for patients with untreated pheochromocytoma and severe peripheral arterial circulatory disturbances.


Population Restrictions and Conditional Use

The medicine is not established and not recommended for the pediatric population (children and adolescents). Older adults may require dosage reductions, particularly if renal function is impaired. Use during pregnancy is generally not recommended, especially in later trimesters, due to documented risks of fetal growth restriction. Use during lactation requires caution due to extensive excretion into breast milk.

Patients with renal impairment require mandatory dose adjustment. Individuals with bronchospastic diseases or diabetes mellitus must use Atenolol with caution due to the potential to aggravate respiratory issues or mask symptoms of hypoglycemia, respectively.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Atenolol’s interaction profile is categorized by its potential for Pharmacodynamic Reinforcement and its unique Pharmacokinetic features related to renal clearance. The interaction data provided below is based strictly on regulatory sources.

Official Interaction Statements

Co-administration with intravenous Verapamil or intravenous Diltiazem is a formally contraindicated combination due to the high risk of severe cardiodepressant effects, as documented in regulatory labels. Antiarrhythmics and Cardiac Glycosides may produce additive pharmacodynamic effects, increasing the risk of pronounced bradycardia and AV conduction disturbances.

Administration Restrictions

Restriction Type Interacting Substance Official Regulatory Requirement
Timing Separation Aluminum Hydroxide/Multivitamins Administration must be separated by at least 2 hours to avoid reduced absorption and decreased exposure.
Procedural Constraint Clonidine Atenolol must be withdrawn several days before the gradual cessation of Clonidine to prevent rebound hypertension.

Population and Clearance Notes

A pharmacokinetic interaction occurs when Atenolol is combined with substances that interfere with gastrointestinal absorption, leading to reduced plasma concentration. Furthermore, due to its active renal secretion, elimination is significantly prolonged in patients with severe renal impairment (CrCl less than 35 mL/min), which increases the potential for concentration-dependent interactions. Official documentation notes that alcohol may enhance the hypotensive effect, and Atenolol may mask symptoms of hypoglycemia in diabetic patients.

Mechanism of Action

Selective Adrenergic Receptor Antagonism

Atenolol is a cardioselective beta1-adrenergic receptor antagonist. It primarily acts by selectively binding to and blocking beta1 receptors, which are abundantly expressed in cardiac tissue. This targeted action inhibits the stimulatory effects of endogenous catecholamines (such as norepinephrine and epinephrine) on the heart .


Modulating Cardiac Conduction and Contractility

By occupying beta1 receptors, atenolol suppresses the molecular cascade that typically increases the heart's activity. This modifies early molecular steps, specifically decreasing the rate of sinus node discharge and slowing atrioventricular (AV) nodal conduction. The physiological consequence is a reduction in both heart rate (negative chronotropy) and the force of heart contraction (negative inotropy), resulting in quantifiable alterations to cardiac output variables.


Influencing the Renin-Angiotensin System

The drug also engages a secondary mechanistic domain. beta1 receptors are located in the juxtaglomerular apparatus of the kidney, and their blockade suppresses the release of the enzyme renin. This effect modulates the initial synthesis of the renin-angiotensin-aldosterone system cascade components.

Dosage and Administration Information

Atenolol is administered via two distinct, officially approved methods: the Oral Tablet used for chronic, long-term management, and the Intravenous (IV) Injection, which is reserved for immediate, acute clinical requirements.

The medicine is primarily taken once daily (OD) for sustained conditions such as hypertension. The standard oral dosing regimen typically starts at 25 mg or 50 mg daily, with maintenance doses stabilized between 50 mg to 100 mg. For acute myocardial infarction, use follows a rapid sequential protocol, beginning with two 5 mg IV injections administered slowly over five minutes each, then transitioning to oral therapy within hours to maintain control. Oral administration often specifies swallowing the tablet whole with liquid, sometimes with the instruction to take it before meals. The IV solution requires no preparation but must be injected at a slow rate.


Administration Adjustments & Procedures

Procedural Requirement Official Instruction
Renal Impairment Dosage must be reduced based on creatinine clearance; daily limits are imposed.
Older Adults Initiation requires a lower starting dose, particularly if renal function is impaired.
Discontinuation Therapy must be gradually tapered over 1–2 weeks; abrupt stopping is an explicit procedural restriction.
Missed Dose Patients are instructed to take the next scheduled dose without doubling up to compensate for the missed amount.

These protocols establish a precise framework for the use of Atenolol, defining the necessary dosage levels, frequency, and population-specific modifications.

Recent Clinical Evidence

Atenolol, a cardioselective beta-1 adrenergic antagonist, remains a widely used medication with established indications for managing hypertension, angina pectoris, and certain cardiac arrhythmias. Recent clinical evidence continues to explore its role, particularly in comparison to newer antihypertensive agents and in specific patient populations.

Comparison in Hypertension Management

While atenolol effectively lowers blood pressure, meta-analyses and systematic reviews have generally indicated that for uncomplicated hypertension, older beta-blockers like atenolol may be associated with a smaller reduction in the risk of cardiovascular events, particularly stroke, compared to other first-line antihypertensive classes such as Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs), and Calcium Channel Blockers. This finding has led some major international clinical guidelines to recommend its use primarily in patients with compelling indications, such as concurrent coronary artery disease, heart failure with reduced ejection fraction, or post-myocardial infarction status. Atenolol is considered suitable for combination therapy when a beta-blocker is required as part of a multi-drug regimen to achieve blood pressure goals.

Use in Specific Conditions

  • Infantile Hemangiomas: Studies have found that oral atenolol demonstrates similar efficacy and a favorable safety profile when compared to propranolol for the treatment of problematic infantile hemangiomas, positioning it as an alternative systemic treatment option.
  • Cardiovascular Outcomes: In a number of studies involving Asian patient populations with chronic progressive diseases, atenolol use has been associated with significantly lower all-cause mortality rates compared to non-users and metoprolol tartrate users. This suggests potential differences in clinical benefit based on ethnic background or genetic factors affecting drug metabolism.
Condition Recent Clinical Finding Summary
Uncomplicated Hypertension Comparable blood pressure reduction, but some evidence suggests a lesser reduction in stroke risk vs. other first-line agents. Primarily reserved for combination therapy or those with co-existing cardiac indications.
Infantile Hemangioma Demonstrates efficacy similar to propranolol with a comparable or lower incidence of adverse events.

Frequently Asked Questions (FAQ)

Common questions about Aten (FAQ)


Q: How quickly does Aten start working after I take it?

According to official product information, a measurable effect on heart activity is often observed within one hour after taking an oral dose. The concentration in the blood typically reaches its highest level within two to four hours, and the blood pressure-lowering effect is reported to persist for at least 24 hours.

Q: Can Aten be taken with other common over-the-counter pain relievers?

Regulatory documents indicate that combining this medicine with certain common pain relievers, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), may potentially lessen its blood pressure-lowering effect. Regulatory documents recommend informing a healthcare professional about all products being used.

Q: Is Aten the same as [Name of a common similar drug, e.g., Metoprolol]?

Aten, whose active ingredient is Atenolol, is classified as a cardioselective beta-1 blocker, meaning it primarily targets receptors in the heart. Official information describes it as a hydrophilic compound with limited ability to cross the blood-brain barrier, characteristics that are noted in the official profile.

Q: Why do doctors prescribe Aten instead of other similar treatments?

Clinical evidence indicates that the medicine may be considered particularly suitable for patients who have co-existing cardiac conditions, such as coronary artery disease or post-myocardial infarction status. It is considered appropriate when a beta-blocker is required as part of a multi-drug regimen to manage blood pressure goals.

Q: Does taking Aten mean I need to avoid certain activities?

Due to common potential side effects like dizziness and fatigue, official warnings describe that activities requiring mental alertness, such as driving or operating machinery, should be approached with caution until a person is aware of how the medicine impacts their alertness.

Q: What is the official stance on Aten's use for anxiety symptoms?

Official regulatory documents define the approved uses for this medicine as high blood pressure (hypertension), chest pain (angina pectoris), and certain irregular heart rhythms. Anxiety symptoms are not listed as an approved indication in the official regulatory product documentation.

Q: What if I forget to take Aten at the same time every day?

The medicine is generally prescribed for once-daily use to help maintain stable blood levels for chronic conditions. While the instruction for a completely missed dose is to skip it and take the next scheduled one, maintaining a consistent time of day can contribute to achieving stable blood levels.

Q: Are there any reported interactions between Aten and common supplements?

The official product documentation notes the importance of informing a healthcare professional about all products being used, including prescription, over-the-counter, vitamin/mineral, and herbal supplements, as these can sometimes affect the way the medicine is absorbed or how it works.

Q: Does the evidence show any themes regarding Aten's use in younger people?

Official documentation explicitly states that the safety and effectiveness of this medicine have not been established in the pediatric population, which includes children and adolescents. For this reason, its use is not generally recommended in these age groups.

Q: Can Aten be used by pregnant women, according to regulatory documents?

Regulatory information documents risks associated with use during pregnancy, especially in the third trimester, including the potential for fetal growth restriction and issues like slow heart rate or low blood sugar in the newborn. The medicine is classified under a category that indicates positive evidence of human fetal risk.

Q: What are the official recommendations if a person experiences blurred vision while on Aten?

Blurred vision is documented as a rare side effect in official prescribing information. Official prescribing information states that visual disturbances should be brought to the attention of a healthcare professional.

Q: How does the official literature describe the effects of Aten on exercise?

The drug works by reducing the heart rate and the force of heart contraction. This action can limit the heart's ability to respond to the demands of physical activity, and research has indicated that it may reduce exercise capacity.

Q: Is it true that Aten can sometimes cause cold hands and feet?

Yes, official regulatory documentation lists 'cold extremities' (cold hands and feet) as a common adverse reaction. This effect was reported to affect between 1% and 10% of patients in clinical trials.

Q: Is it necessary to take Aten with food?

While the primary instructions for the tablets mention they are sometimes administered with instructions to take them before meals, there is no official, universal requirement that the medicine must be taken with food. It is typically swallowed whole with liquid.

Q: What does official guidance say about using Aten during breastfeeding?

Official guidance advises caution during lactation because the medicine is known to be extensively excreted into breast milk. Potential risks for the infant, such as slow heart rate (neonatal bradycardia) and low blood sugar (hypoglycemia), are noted.

Q: Does research show any link between Aten and weight changes?

The official product label does not typically list weight changes in the common adverse reaction categories. However, some older beta-blockers are associated with a potential for weight change, which has been a theme examined in post-marketing reports.

Q: What is Aten's safety classification for children?

Official information states that the medicine is not established and is not recommended for the pediatric population, which includes children and adolescents. The safety profile has not been determined for use in these age groups.

Q: Do official summaries describe Aten as habit-forming?

Regulatory documents do not classify the medicine as a controlled substance. Furthermore, official summaries do not describe the medicine as habit-forming or having the potential for drug dependence.

Q: What are the common themes in research about Aten's effectiveness for its main use?

Research themes consistently show that the medicine is effective at reducing blood pressure and is a standard treatment following a heart attack. Current evidence emphasizes its primary recommendation for patients who also have concurrent cardiac conditions.

Q: Does the package insert mention any specific time of day for taking Aten?

The official package insert recommends once-daily dosing (OD). There is no official, mandatory time of day, such as morning or evening, specified for its chronic, long-term use.

Q: What does 'use conditions' mean in relation to Aten?

'Use conditions' is a regulatory term that refers to the required protocols and modifications that govern how a medicine should be administered. This includes procedural requirements like mandatory dose reductions for patients with kidney impairment and the protocol for gradually stopping treatment.

How should Aten be stored and disposed of?

Atenolol tablets must be stored at controlled room temperature, typically 20 to 25 C (68 to 77 F), with excursions allowed up to 30 C (86 F). Storage conditions may require the product to not be stored above 25 C and to be kept from freezing.

Protection and Packaging

The medication must be stored in its original container and kept tightly closed to protect it from light and moisture. As a mandatory safety requirement, the product must be stored out of the reach of children, often requiring a child-resistant closure.

Disposal

Unused or expired Atenolol must not be allowed to enter the sewer system or surface water, and should not be discarded in household trash. Disposal must be conducted according to local regulations, often by consulting a healthcare professional or pharmacist for guidance on take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aten found in:

A-Z Index: